The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients

Short summary

Early administration of tranexamic acid (TXA) to bleeding trauma patients within 3 hours of injury significantly reduced all-cause mortality by 9% (RR 0.91) and death due to bleeding by 15% (RR 0.85), saving an estimated 755 life-years per 1000 patients in the UK at a cost of $64 per life-year gained.

AI-generated from the title and abstract; the full text is not read.